CohBar — Shareholder Meeting (June 2015)
41 slides from CohBar's shareholder meeting presentation, Jun 9, 2015
Slide 1: CohBar Annual Shareholder Presentation June 9th, 2015
CohBar Annual Shareholder Presentation June 9 th , 2015
Slide 2: Legal Disclaimer
This presentation includes forward - looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future plans, intentions, expectations, business prospects and opportunities. Examples of suc
Slide 3: Overview
Overview CohBar: Increasing healthy life span Albion Fitzgerald - Chairman CohBar’s groundbreaking discoveries Hassy Cohen, MD - Founder CohBar’s path to the clinic: from discovery to therapeutic Ken Cundy, PhD - CSO CohBar’s Science team, Strategy and Progress to date Jon Stern - CEO Biotech Indust
Slide 4: CohBar – Breakthrough science to increase healthy life span
CohBar – Breakthrough science to increase healthy life span Our founders have been doing groundbreaking work for the past 15+ years in the intersecting areas of geriatrics, metabolism, genetics, and biology resulting in breakthrough discoveries about mitochondria , the powerhouses of human cells, an
Slide 5: Lifespan vs. Healthspan: Years of Health vs. Disease
Graph ©Mark Collins - Glenn Foundation Lifespan vs. Healthspan Years of Health vs. Disease Years of Health vs Disease 55 90 75 55 30 10 10 45 Now Ideal Outcome (centenarians) Or even Nightmare 5
Slide 6: Mortality from non-communicable diseases of aging has increased with longevity
Mortality from non - communicable diseases of aging has increased along with increased longevity Source: NIH 10000 1000 100 10 1 0 100000 Deaths per 100,000 per year Heart disease Cancer Stroke Emphysema Pneumonia Diabetes Accidents Kidney disease Alzheimer’s Disease Age and age - related diseases A
Slide 7: Non-communicable Diseases: A global epidemic and enormous economic burden
Non - communicable Diseases A global epidemic and enormous economic burden 7 • The four main non - communicable diseases — cardiovascular diseases, diabetes, cancers and chronic respiratory diseases — are now becoming a global epidemic. (WHO 2011) • By 2030, non - communicable diseases are projected
Slide 8: Centenarians and Offspring Have Lower Prevalence of Diseases
From a Groundbreaking Study by Dr. Nir Barzilai: Centenarians and Offspring Have Lower Prevalence of Diseases 8 • 1 in 10,000 lives to 100 years old • Centenarians have less or similar prevalence of diseases compared to people who are 20 to 30 years younger. • Centenarian later - life and end - of -
Slide 9: Mitochondria and Mitochondria Derived Peptides
Core component of metabolism Mitochondrial function declines with age/damage Metabolic dysfunction with mitochondrial impairment is a significant aspect of major age - related diseases: - Diabetes, cardiovascular diseases - Neurodegeneration, Alzheimer’s - Recognized as a contributing factor in canc
Slide 10: Growing recognition of the significance of mitochondria in disease and aging
Growing recognition of the significance of mitochondria in disease and aging Mitochondrial Link Between High Glucose And Metabolic Disease Global Diabetes Rates Are Rising as Obesity Spreads JUNE 8, 2015 10
Slide 11: Founders: leading experts in biology of aging and mitochondrial science
And of our founders, which include three of the world’s leading experts in the biology of aging and mitochondrial science The Mitochondrial - Derived Peptide MOTS - c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance C. Lee and P. Cohen A CONVERSATION WITH/Nir Barzilai: It's
Slide 12: CohBar's unique approach to mitochondria-based therapeutics
Mitochondria increasingly targeted by biotech: CohBar’s unique approach optimizes mitochondrial - derived peptides to develop multiple mitochondria - based therapeutics CohBar’s approach : Find the drugs within the mitochondria to treat the disease Mitochondria - targeted therapeutics: Optimized pep
Slide 13: CohBar Founder – Dr. Pincus “Hassy” Cohen
CohBar Founder – Dr. Pincus “Hassy” Cohen • Dean of the Davis School of Gerontology, University of Southern California • Executive Director of the Ethel Percy Andrus Gerontology Center • William and Sylvia Kugel Dean’s Chair in Gerontology • MD degree from the Technion Israel Institute of Technology
Slide 14: MDPs – A New Untapped Field in Biology
MDPs – A New Untapped Field in Biology MDP Biological Effects: • MDPs influence cellular activities by acting as messengers between cells, triggering intra - cellular changes • MDPs have metabolic effects, neuro - protective effects, cyto - protective effects and anti - inflammatory effects • Humani
Slide 15: MOTS-c plays a significant role in regulation of metabolism
MOTS - c plays a significant role in regulation of metabolism Potential source of MBTs to treat Type 2 Diabetes, obesity, and fatty liver. MOTS - c prevents weight gain in mice on a high fat diet The Company plans to advance research on MOTS - c and novel MBT analogs of MOTS - c as our lead program,
Slide 16: MOTS-c – A Key Regulator of Metabolism
MOTS - c Glucose Regulation Fatty Acids Amino Acids Cell Death DNA Synthesis Mitochondrial Metabolism MOTS - c - A Key Regulator of Metabolism 16
Slide 17: MOTS-c shows proof of principle in obesity model
MOTS - c, a key regulator of metabolism, shows proof of principle in obesity model “MOTS - c, a new mitochondrial - derived peptide hormone that prevents obesity caused by a high - fat diet and stimulates the metabolism in the same way as exercise.” 17
Slide 18: MOTS-c reverses insulin resistance, inhibits tumor growth in mice
MOTS - c reverses age - dependent insulin resistance, inhibits human prostate/breast tumor growth in mice MOTS - c Soleus Muscle 2 - DG Uptake (3 mo. Vs 12 mo. Mice) MOTS - c reverses age - dependent insulin resistance in mice MOTS - c inhibits human prostate and breast tumor growth in mice 18
Slide 19: SHLP-6 suppresses cancer progression in mice
SHLP - 6 suppresses cancer progression in mice Potential MBTs to treat prostate and breast cancer The Company plans to advance its research on SLHP - 6 and novel MBT analogs of SHLP - 6 with the potential for the treatment of cancer. SHLP - 6 slows tumor growth by killing cancer cells and reducing t
Slide 20: SHLP-2 protects neuronal cells from toxicity in vitro
SHLP - 2 protects neuronal cells from toxicity in vitro Potential MBT for the treatment of Alzheimer's disease. Increasing SHLP - 2 reduces dying cells 20
Slide 21: Humanin effective in animal models of atherosclerosis, diabetes, neurodegeneration
Humanin - effective in animal models of atherosclerosis, Type 2 Diabetes, neurodegeneration Potential MBT to treat a variety of diseases Humanin analogue Aortic Arch Plaque Treatment with Humanin analogue reduces arterial plaque Plaque reduction vs. Control 21
Slide 22: Exceptional Health and Humanin
Exceptional Health and Humanin The development of assays to measure humanin levels in plasma enabled the observation of humanin levels in aged patients and patients with poor endothelial function associated with cardiovascular diseases . • Humanin declines with age but is higher in offspring of cent
Slide 23: The Expanded Mitochondrial Genome
The Expanded Mitochondrial Genome Many potential new regulatory peptides (MDP’s) 7 8 3 3 5 4 6 5 4 5 7 8 1 6 Mutations described in Various Diseases 7 8 3 3 5 4 6 5 4 5 7 8 1 6 Mutations described in Various Diseases 23
Slide 24: CohBar CSO: Kenneth Cundy, PhD
CohBar CSO : Kenneth Cundy, PhD Taking the discoveries to the clinic • Joined CohBar in November 2014 as Chief Scientific Officer (CSO) • CSO and SVP for Xenoport, Inc. (NASDAQ:XNPT), Gilead Sciences, Sterling Drug • Ph.D. in pharmaceutical sciences from University of Kentucky • Patents/Publications
Slide 25: CohBar's Preclinical Plan
Selection of an MBT drug candidate: • Evaluation of existing MDPs and any newly discovered MDPs • Determination of initial activity in efficacy models • Prioritization of potential lead molecules • Synthesis of new analogs (MBTs) • Iterative evaluation of stability, pharmacokinetics, and efficacy •
Slide 26: MDP Optimization and Development into MBTs
CohBar MBT Optimization Process: • Synthesis of analogs of native MDP • Physicochemical Properties • Solubility • Chemical stability • Resistance to Enzymatic Degradation • Stability in tissues • Efficacy • In vitro cell - based assays • In vivo disease models • Pharmacokinetics • Half - life, distr
Slide 27: Criteria for Selection of Drug Targets
Criteria for Selection of Drug Targets Identify a target indication with: Preclinical evidence of activity for a CohBar MBT Large established market with potential for growth Unmet need that can be addressed by CohBar MBTs Potential for differentiation from current therapies Proven acceptance of inj
Slide 28: Global Therapeutic Market Opportunities
CohBar – Global Therapeutic Market Opportunities 0 10 20 30 40 50 60 70 2014 2015 2016 2017 2018 2019 Cardiocascular Disease ($50-40b, -4% CAG) Type 2 Diabetes ($42-59b, 8% CAG) Breast Cancer ($12-26b, 23% CAG) Prostate Cancer (6.5-12b, 17% CAG) Alzheimer's Disease ($4.5-5b, 1% CAG) Obesity ($.6-3B,
Slide 29: CohBar R&D Resources
USC Leonard Davis School of Gerontology University of Cincinnati Founders, SAB Members and Consultants Market Research & Competitive Intelligence CROs Albert Einstein College of Medicine CohBar R&D Resources CohBar Internal R&D 29
Slide 30: The CohBar Pipeline
The CohBar Pipeline MDP Potential Indications Stage Observed Effects MOTS - c Type 2 Diabetes Obesity Fatty Liver Cancer & Proliferative Diseases Preclinical Anti - diabetic, insulin sensitizer, prevents obesity and fatty - liver in mice Inhibits prostate cancer growth, (pro - apoptotic, anti - angi
Slide 31: Projected Development Timeline and Milestones
Projected Development Timeline and Milestones 31
Slide 32: CohBar CEO - Jon Stern
CohBar CEO - Jon Stern Building CohBar’s Infrastructure • Started working with the company in 2012 • Senior business executive, over 30 years of diversified management experience • Early stage companies - CEO and Founder of Cine Coasters, Inc • B.S. in Business Administration from The University of
Slide 33: Significant progress over the past year
Significant p rogress over the past year Building the Team Enhanced scientific leadership with the addition of Kenneth Cundy, Ph.D., Chief Scientific Officer and Kent Grindstaff, Ph.D., VP Biology Opened new modern laboratory in Menlo Park, CA (Silicon Valley) Developing the Network Completed agreem
Slide 34: Strategy going forward
Strategy going forward Advance to the Clinic Select lead MDP and allocate majority of resources toward its development Initiate clinical evaluation of our first MBT candidate within 2 - 3 years Expand and Exploit our Network Grow our team of advisors and research partners Develop relationships/partn
Slide 35: CohBar's Co-Founders, SAB & Consultants
CohBar’s Co - Founders, SAB & Consultants 35 John Amatruda , M.D. Merck Bayer Frank Calzone, Ph.D. Amgen REMD BioTherapeutics Nick Livingston. Ph.D. GSK, Bayer NovaTarg Therapeutics Paul Aisen , M.D. UC San Diego NeuroPhage David Sinclair, Ph.D. Harvard Medical School Sirtris Pharmaceuticals Genocea
Slide 36: CohBar's Independent Directors
CohBar’s Independent Directors Life Sciences, early - stage and public company experience Marc Goldberg – independent Director since November 2014 Managing Director at BioVentures Investors (life science focused venture and private equity investment firm) Founding President of Massachusetts Biotechn
Slide 37: Biotech Industry Risk/Return Model
Biotech Industry Risk/Return Model Variable Timeframe/Cost Intermediate time frame High Cost 5 - 8 yrs 5 yrs Discovery Late - Stage Clinical Trials Through Commercialization 2 - 4 yrs Short Timeframe Moderate Cost Time Return On Investment Lead Identification Through Early - Stage Clinical Trials Va
Slide 38: Sample Early-stage Drug Discovery Company Valuations
Sample Early - stage Drug Discovery Company Valuations Company Disease Date Preclinical Market Cap Market Cap Today Percent Increase Alnylam Various 2010 $700m $11,700m 1,500% Verastem Cancer 2012 IPO $224m $317m 40% Agios Pharma Cancer 2013 IPO $942m $4,570m 385% Bluebird Various 2013 IPO $600m $6,
Slide 39: Potential Value Drivers Going Forward
Potential Value Drivers Going Forward CohBar Science and Pipeline: Pre - clinical data and publications on CohBar drugs Advancement of lead program into human trials Additional IP in the mitochondria space Industry Awareness and Relationships: Recognition as leader in mitochondria and aging Interest
Slide 40: CohBar – Breakthrough science to increase healthy life span
CohBar – Breakthrough science to increase healthy life span Our founders have been doing groundbreaking work for the past 15+ years in the intersecting areas of geriatrics, metabolism, genetics, and biology resulting in breakthrough discoveries about mitochondria , the powerhouses of human cells, an
Slide 41: Questions?
Questions? 41